Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

This study is testing a combination of treatments given before surgery — envafolimab (an immunotherapy drug) plus albumin-bound paclitaxel and carboplatin (chemotherapy drugs) — for people with locally advanced esophageal squamous cell carcinoma (cancer of the food pipe) that is eligible for surgical removal. **You may be eligible if...** - You are 18 or older - You have esophageal squamous cell carcinoma confirmed by biopsy - Your cancer is locally advanced (T2–T4a stage) and you are a candidate for surgery - You have not previously received any immunotherapy, chemotherapy, targeted therapy, or radiation for this cancer - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - You have active autoimmune disease - You have had a previous or concurrent cancer - You have had major surgery or significant trauma in the past 28 days - You have bleeding disorders or active esophageal variceal bleeding - You have significant fluid build-up in the abdomen or chest that cannot be controlled with medication - You have a known allergy to any of the study drugs Talk to your doctor to see if this trial is right for you.